

Highly Specialised Technology Committee Interests Register

Topic: Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913]

Publication Date: 2 April 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Emtiyaz Chowdhury	Committee Member	Non-financial professional	<p>Emtiyaz declared the following:</p> <p>I am employee of Parexel. Parexel provides services to the manufacturer for olipudase alfa. I have had no knowledge or involvement of any services Parexel has provided to this manufacturer for this specific technology.</p>	<p>15/09/2023</p> <p>07/11/2024</p>	It was agreed that his declaration would not prevent Emtiyaz from participating in discussions on this evaluation.
Dr Paul Arundel	Committee Member	Non-financial professional	<p>Dr Arundel declared the following:</p> <p>I will be principal investigator (PI) for a study in set-up at my institution for which Sanofi is the sponsor. However, the study concerns a different technology and disease area. Study for which I will be PI is "A longitudinal study to evaluate growth measurements and digital biomarkers in pediatric participants with achondroplasia", study number OBS16647. The condition is</p>	15/09/2023	It was agreed that his declaration would not prevent Dr Arundel from participating in discussions on this evaluation.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			achondroplasia and study is a non-drug study but one which is expected to lead to recruitment of subjects to a future drug study (not olipudase alfa). All my activity in relation to the study is through my NHS role and I do not receive any additional payments outside my NHS salary for study-related activity.		
Professor Simon Jones	Clinical Expert	Direct & Indirect financial	<p>Professor Jones declared the following:</p> <p>I have been paid to act as a consultant on advisory boards to Sanofi around the use of the product Olipudase and the treatment of ASMD</p>	<p>29/07/2022</p> <p>07/11/2024</p>	It was agreed that his declaration would not prevent Professor Jones from providing expert advice to the committee.
Dr Robin Lachmann	Clinical Expert	Direct financial	<p>Dr Lachmann declared the following:</p> <p>I have received honoraria for speaking and travel expenses from Sanofi Genzyme.</p> <p>I have received consulting fees from Sanofi Genzyme related to</p>	<p>29/09/2022</p> <p>07/11/2024</p>	It was agreed that his declarations would not prevent Dr Lachmann from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>olipudase alfa for acid sphingomyelinase deficiency.</p> <p>I have received consulting fees from Biomarin related to their gene therapy programme for phenylketonuria.</p> <p>I have received honoraria for speaking from Amicus.</p> <p>I have received consulting fees and honoraria for speaking from Takeda for work related to professional development programmes.</p>		